These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. [Medication of the month. A new combined oral contraceptive containing estradiol valerate and dienogest (Qlaira)]. Gaspard U; Pintiaux A; Kridelka F Rev Med Liege; 2010 Dec; 65(12):706-13. PubMed ID: 21287768 [TBL] [Abstract][Full Text] [Related]
8. [Potential advantages of triphasic combined oral contraceptives in the light of recent epidemiological and endocrinometabolic data]. Gaspard U; Dubois M Contracept Fertil Sex (Paris); 1982 Sep; 10(9):551-60. PubMed ID: 12311606 [TBL] [Abstract][Full Text] [Related]
9. Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel. Klipping C; Duijkers I; Parke S; Mellinger U; Serrani M; Junge W Drugs R D; 2011; 11(2):159-70. PubMed ID: 21679006 [TBL] [Abstract][Full Text] [Related]
10. Estradiol valerate and dienogest: a novel four-phasic oral contraceptive pill effective for pregnancy prevention and treatment of heavy menstrual bleeding. Micks E; Jensen JT Womens Health (Lond); 2011 Sep; 7(5):513-24. PubMed ID: 21879819 [TBL] [Abstract][Full Text] [Related]
11. [Influence of progestins on adverse effects of oral contraceptives]. Wynn V Contracept Fertil Sex (Paris); 1985 Jan; 13(1 Suppl):425-30. PubMed ID: 12280210 [TBL] [Abstract][Full Text] [Related]
12. The formulation of oral contraceptives: does the amount of estrogen make any clinical difference? Speroff L Johns Hopkins Med J; 1982 May; 150(5):170-6. PubMed ID: 7043035 [TBL] [Abstract][Full Text] [Related]
13. Contraception containing estradiol valerate and dienogest--advantages, adherence and user satisfaction. Graziottin A Minerva Ginecol; 2014 Oct; 66(5):479-95. PubMed ID: 25245997 [TBL] [Abstract][Full Text] [Related]
14. Natazia--a new oral contraceptive. Med Lett Drugs Ther; 2010 Sep; 52(1346):71-2. PubMed ID: 20814403 [No Abstract] [Full Text] [Related]
15. Evaluation of a new estradiol oral contraceptive: estradiol valerate and dienogest. Jensen JT Expert Opin Pharmacother; 2010 May; 11(7):1147-57. PubMed ID: 20367275 [TBL] [Abstract][Full Text] [Related]
16. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
17. Estrogens and progestins: background and history, trends in use, and guidelines and regimens approved by the US Food and Drug Administration. Stefanick ML Am J Med; 2005 Dec; 118 Suppl 12B():64-73. PubMed ID: 16414329 [TBL] [Abstract][Full Text] [Related]
18. Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation. Bastianelli C; Farris M; Rosato E; Brosens I; Benagiano G Expert Rev Clin Pharmacol; 2018 Nov; 11(11):1085-1098. PubMed ID: 30325245 [TBL] [Abstract][Full Text] [Related]
19. [Thirty years after the appearance of the first oral contraceptive, clinical and biological analysis of a new estrogen-progestin combination, a three phase pill containing gestodene]. Belaisch J; Hommais-loufrani B Fertil Contracept Sex; 1988 Apr; 16(4 Suppl):1-8. PubMed ID: 12342078 [TBL] [Abstract][Full Text] [Related]
20. Normalization of blood loss in women with heavy menstrual bleeding treated with an oral contraceptive containing estradiol valerate/dienogest. Fraser IS; Jensen J; Schaefers M; Mellinger U; Parke S; Serrani M Contraception; 2012 Aug; 86(2):96-101. PubMed ID: 22240178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]